Results 201 to 210 of about 65,793 (248)
Some of the next articles are maybe not open access.
Clinical Science, 1976
1. A new method of destroying thrombi in blood vessels by ultrasound and simultaneously removing them is reported. 2. Experiments were performed in twenty dogs with artificial thrombi in the iliac and femoral arteries and veins. The length of the thrombi ranged from 4 to 5 cm and the age from 12 h to 10 days. The unit used consisted of a
G, Trübestein +5 more
openaire +2 more sources
1. A new method of destroying thrombi in blood vessels by ultrasound and simultaneously removing them is reported. 2. Experiments were performed in twenty dogs with artificial thrombi in the iliac and femoral arteries and veins. The length of the thrombi ranged from 4 to 5 cm and the age from 12 h to 10 days. The unit used consisted of a
G, Trübestein +5 more
openaire +2 more sources
Archives of Neurology, 1996
On June6,1996, the Peripheral and Central Nervous System Drug Advisory Committee to the US Food and Drug Administration (FDA) voted 10 to 0 that tissue-type plasminogen activator (t-PA [lateplase]) is safe and effective therapy for acute ischemic stroke.
openaire +2 more sources
On June6,1996, the Peripheral and Central Nervous System Drug Advisory Committee to the US Food and Drug Administration (FDA) voted 10 to 0 that tissue-type plasminogen activator (t-PA [lateplase]) is safe and effective therapy for acute ischemic stroke.
openaire +2 more sources
Archives of Neurology, 1996
Thrombolytictherapy for stroke signals a breakthrough, through clots and nihilistic attitudes. Although a systematic approach to stroke care as exemplified by stroke units has been shown to improve outcomes, 1 recombinant tissue-type plasminogen activator (rt-PA) is the first drug to make a demonstrable difference to stroke.
openaire +3 more sources
Thrombolytictherapy for stroke signals a breakthrough, through clots and nihilistic attitudes. Although a systematic approach to stroke care as exemplified by stroke units has been shown to improve outcomes, 1 recombinant tissue-type plasminogen activator (rt-PA) is the first drug to make a demonstrable difference to stroke.
openaire +3 more sources
Unstable angina and thrombolysis
Chest, 1990Unstable angina occurs in a heterogeneous population of patients. In the subset of patients with recent rest angina, both angiographic and angioscopic studies have suggested that coronary artery thrombus is often present and serves as a predictor of subsequent adverse clinical events, including recurrent angina, myocardial infarction, the need for ...
openaire +2 more sources
Thrombolysis for Pulmonary Embolism
New England Journal of Medicine, 1991The primary therapy for acute pulmonary embolism is anticoagulation with heparin and warfarin to prevent additional thromboembolism.
openaire +3 more sources